HuGE Literature Finder
Records
1
-
6
Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease. Brain and behavior 2018 Jun e01008. McDonell Katherine E, van Wouwe Nelleke C, Harrison Madaline B, Wylie Scott A, Claassen Daniel |
Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. Parkinsonism & related disorders 2015 Nov . Hassan Anhar, Heckman Michael G, Ahlskog J E, Wszolek Zbigniew K, Serie Daniel J, Uitti Ryan J, van Gerpen Jay A, Okun Michael S, Rayaprolu Sruti, Ross Owen |
DRD3 Ser9Gly and HS1BP3 Ala265Gly are not associated with Parkinson disease. Neuroscience letters 2009 Sep 461 (2): 74-5. Keeling Brett H, Vilariño-Güell Carles, Ross Owen A, Wszolek Zbigniew K, Uitti Ryan J, Farrer Matthew |
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. European journal of clinical pharmacology 2009 Jul 65 (7): 679-83. Liu Ying-Zi, Tang Bei-Sha, Yan Xin-Xiang, Liu Jie, Ouyang Dong-Sheng, Nie Li-Nuo, Fan Lan, Li Zhi, Ji Wei, Hu Dong-Li, Wang Dan, Zhou Hong-H |
Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2008 Sep 147B (6): 890-7. Al Hadithy Asmar F, Wilffert Bob, Stewart Roy E, Looman Nicole M, Bruggeman Richard, Brouwers Jacobus R, Matroos Glenn E, van Os Jim, Hoek Hans W, van Harten Peter |
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Archives of neurology 2001 Feb 58 (2): 209-13. Goetz C G, Burke P F, Leurgans S, Berry-Kravis E, Blasucci L M, Raman R, Zhou |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 09, 2022
- Content source: